Skip to main content

Abstract P252: Discharge Antithrombotic Therapy for Ischemic Stroke Patients With Prior Aspirin Failure

Publication ,  Conference
Xian, Y; Xu, H; Bhatt, DL; Fonarow, GC; Smith, EE; Matsouaka, R; Lytle, B; Peterson, ED; Schwamm, LH
Published in: Stroke
March 2021

Aspirin is one of the most commonly used medications for cardiovascular disease and stroke prevention. Many older patients who present with a first or recurrent stroke are already on aspirin monotherapy, yet little evidence is available to guide antithrombotic strategies for these patients. Using data from the American Heart Association Get With The Guidelines-Stroke Registry, we described discharge antithrombotic treatment pattern among Medicare beneficiaries without atrial fibrillation who were discharged alive for acute ischemic stroke from 1734 hospitals in the United States between October 2012 and December 2017. Of 261,634 ischemic stroke survivors, 100,016 (38.2%) were on prior aspirin monotherapy (median age 78 years; 53% women; 79.4% initial stroke and 20.6% recurrent stroke). The most common discharge antithrombotics (Figure) were 81 mg aspirin monotherapy (20.9%), 325 mg aspirin monotherapy (18.2%), clopidogrel monotherapy (17.8%), and dual antiplatelet therapy (DAPT) of 81 mg aspirin and clopidogrel (17.1%). Combined, aspirin monotherapy, clopidogrel monotherapy, and DAPT accounted for 86.8% of discharge antithrombotics. The rest of 13.2% were discharged on either aspirin/dipyridamole, warfarin or non-vitamin K antagonist oral anticoagulants with or without antiplatelet, or no antithrombotics at all. Among patients with documented stroke etiology (TOAST criteria), 81 mg aspirin monotherapy (21.2-24.0%) was the most commonly prescribed antithrombotic for secondary stroke prevention. The only exception was those with large-artery atherosclerosis, in which, 25.3% received DAPT of 81 mg aspirin and clopidogrel at discharge. Substantial variations exist in discharge antithrombotic therapy for secondary stroke prevention in ischemic stroke with prior aspirin failure. Future research is needed to identify best management strategies to care for this complex but common clinical scenario.

Duke Scholars

Published In

Stroke

DOI

EISSN

1524-4628

ISSN

0039-2499

Publication Date

March 2021

Volume

52

Issue

Suppl_1

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related Subject Headings

  • Neurology & Neurosurgery
  • 4201 Allied health and rehabilitation science
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Xian, Y., Xu, H., Bhatt, D. L., Fonarow, G. C., Smith, E. E., Matsouaka, R., … Schwamm, L. H. (2021). Abstract P252: Discharge Antithrombotic Therapy for Ischemic Stroke Patients With Prior Aspirin Failure. In Stroke (Vol. 52). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1161/str.52.suppl_1.p252
Xian, Ying, Haolin Xu, Deepak L. Bhatt, Gregg C. Fonarow, Eric E. Smith, Roland Matsouaka, Barbara Lytle, Eric D. Peterson, and Lee H. Schwamm. “Abstract P252: Discharge Antithrombotic Therapy for Ischemic Stroke Patients With Prior Aspirin Failure.” In Stroke, Vol. 52. Ovid Technologies (Wolters Kluwer Health), 2021. https://doi.org/10.1161/str.52.suppl_1.p252.
Xian Y, Xu H, Bhatt DL, Fonarow GC, Smith EE, Matsouaka R, et al. Abstract P252: Discharge Antithrombotic Therapy for Ischemic Stroke Patients With Prior Aspirin Failure. In: Stroke. Ovid Technologies (Wolters Kluwer Health); 2021.
Xian, Ying, et al. “Abstract P252: Discharge Antithrombotic Therapy for Ischemic Stroke Patients With Prior Aspirin Failure.” Stroke, vol. 52, no. Suppl_1, Ovid Technologies (Wolters Kluwer Health), 2021. Crossref, doi:10.1161/str.52.suppl_1.p252.
Xian Y, Xu H, Bhatt DL, Fonarow GC, Smith EE, Matsouaka R, Lytle B, Peterson ED, Schwamm LH. Abstract P252: Discharge Antithrombotic Therapy for Ischemic Stroke Patients With Prior Aspirin Failure. Stroke. Ovid Technologies (Wolters Kluwer Health); 2021.

Published In

Stroke

DOI

EISSN

1524-4628

ISSN

0039-2499

Publication Date

March 2021

Volume

52

Issue

Suppl_1

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related Subject Headings

  • Neurology & Neurosurgery
  • 4201 Allied health and rehabilitation science
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology